PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Calliditas Therapeutics (CALT)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US13124Q1067

Sector

Healthcare

IPO Date

Jun 5, 2020

Highlights

Market Cap

$1.10B

EPS (TTM)

-$1.76

Total Revenue (TTM)

$855.26M

Gross Profit (TTM)

$787.80M

EBITDA (TTM)

-$234.27M

Year Range

$16.00 - $43.00

Target Price

$39.25

Short %

0.02%

Short Ratio

0.30

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
CALT vs. ASM
Popular comparisons:
CALT vs. ASM

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Calliditas Therapeutics, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-4.00%-2.00%0.00%2.00%4.00%Aug 25SeptemberSep 08Sep 15Sep 22
0.68%
2.32%
CALT (Calliditas Therapeutics)
Benchmark (^GSPC)

Returns By Period


CALT

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

3.96%

1M

1.97%

6M

9.03%

1Y

22.16%

5Y*

12.60%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of CALT, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-13.84%-3.88%-1.45%-5.09%100.55%-2.50%-1.38%4.34%55.38%
202312.94%-3.59%29.50%-2.63%-27.38%-6.55%24.25%-14.74%8.82%-10.73%6.44%48.38%51.44%
2022-14.34%-6.91%-3.06%-23.15%21.35%-0.56%5.07%-11.53%-8.08%-1.75%21.95%-6.44%-31.34%
2021-19.66%3.92%-1.80%7.38%-0.00%-0.51%-1.36%-2.99%-23.28%-24.51%12.68%34.64%-26.35%
202018.37%-1.51%-0.61%5.68%-2.75%57.03%-8.27%71.53%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 84, CALT is among the top 16% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of CALT is 8484
Overall Rank
The Sharpe Ratio Rank of CALT is 7676
Sharpe Ratio Rank
The Sortino Ratio Rank of CALT is 9191
Sortino Ratio Rank
The Omega Ratio Rank of CALT is 8888
Omega Ratio Rank
The Calmar Ratio Rank of CALT is 8989
Calmar Ratio Rank
The Martin Ratio Rank of CALT is 7878
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Calliditas Therapeutics (CALT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
No data
CALT
^GSPC

There is not enough data available to calculate the Sharpe ratio for Calliditas Therapeutics. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio1.502.002.50Aug 25SeptemberSep 08Sep 15Sep 22
1.37
2.73
CALT (Calliditas Therapeutics)
Benchmark (^GSPC)

Dividends

Dividend History


Calliditas Therapeutics doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-5.00%-4.00%-3.00%-2.00%-1.00%0.00%Aug 25SeptemberSep 08Sep 15Sep 22
-3.73%
-0.13%
CALT (Calliditas Therapeutics)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Calliditas Therapeutics. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Calliditas Therapeutics was 68.62%, occurring on Oct 20, 2022. Recovery took 401 trading sessions.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-68.62%Dec 1, 2020476Oct 20, 2022401May 28, 2024877
-21.07%Oct 14, 202013Oct 30, 20206Nov 9, 202019
-15.88%Jul 23, 20205Jul 29, 202050Oct 8, 202055
-8.23%Jun 7, 202435Jul 29, 202425Sep 3, 202460
-7.01%Nov 11, 20209Nov 23, 20204Nov 30, 202013

Volatility

Volatility Chart

The current Calliditas Therapeutics volatility is 6.08%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


4.00%4.50%5.00%5.50%6.00%6.50%Aug 25SeptemberSep 08Sep 15Sep 22
6.08%
4.00%
CALT (Calliditas Therapeutics)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Calliditas Therapeutics over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Calliditas Therapeutics.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab